Dupuytren's contracture companies focus on providing solutions for Dupuytren's disease, a condition that causes the thickening and tightening of the connective tissues in the hand, leading to the formation of nodules and contractures. These companies develop injectable medications, minimally invasive procedures, and surgical options to address Dupuytren's contracture and restore hand function for affected individuals.
Endo International Enrolled the first patient in their GRASP-DC registry, a large-scale study aiming to collect real-world data on DC treatment outcomes and inform future treatment strategies. Received FDA approval for their Xiaflex (collagenase clostridium histolyticum) for the treatment of Dupuytren's contracture of the fingers.
BioSpecific Technologies Corp Acquired by Endo International, expanding their portfolio of DC treatment options with Xiaflex. Continuing research and development on next-generation collagenase therapies for DC.
Auxilium Pharmaceuticals, Completed the acquisition of BioSpecific Technologies Corp., now integrated into Endo International. Their Xiaflex therapy remains a widely used option for collagenase injection in DC treatment.
Integra Lifesciences Holdings Corp Offers various surgical instruments and implants for DC surgery, including minimally invasive options. Partnering with surgeons and researchers to develop and improve surgical techniques for DC.
Arthrex, Provides a range of surgical instruments and implant systems for DC surgery, including advanced needle options for collagenase injection. Focusing on innovative technologies and techniques to improve surgical outcomes and minimize patient downtime.
Dupuytren’s Contracture Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)